Nutri5® and Brain Health related to treatment of menopausal symptoms
(Thomson Reuters ONE) - Earlier this year, the BBC reported that "HRT - Hormone ReplacementTherapy - can shrink women's brains"1, after a study was publishedwhich showed that brain volume in women taking HRT was smaller in twokey areas involved in thinking and memory.This comes in addition to earlier results from the Women's HealthInitiative (WHI) Memory Study2 that linked HRT to an increased riskof memory loss and dementia, and an article in the Lancet3 whichconcluded that HRT "substantially increases the risk of dementia ofany cause and cognitive* decline" (* memory, thinking andunderstanding).This adds to the growing body of evidence that the risks of HRT faroutweigh any perceived benefits, evidence that Nutri Pharma feelsneeds to be brought to the attention of the 150,000 women in Norwayand millions of women across Europe who are still being prescribedthis treatment.Nutri5® is Nutri Pharma's natural product for the relief ofmenopausal symptoms, shown to be effective in an open pilot study. Inaddition to reducing menopausal symptoms, improving heart health andreducing the risk of osteoporosis, clinical trials4 on soy dietscontaining high levels of soy isoflavones like those found in Nutri5®have also shown that, unlike HRT, these can actually improve thecognitive function of post-menopausal women (aged 45+).Dr. Bernt Rognlien of Balderklinikken, responsible for the pilotstudy on Nutri5 in Norway says "these new findings confirm that thedifferent effects of the two treatments on brain health can beconsiderable and provide yet another reason for adopting a morenatural approach to the treatment of menopausal symptoms."Nutri Pharma has noted both the adverse effects of HRT and thepotentially positive effects of Nutri5® on cognition and isconsidering whether a clinical trial can be designed to directlycompare the two approaches to the treatment of menopausal symptoms.1. http://news.bbc.co.uk/1/hi/health/7825116.stm andResnick et al. Neurology (2009) 72:135-1422. Schumaker et al. JAMA. 2003 May 28;289(20):2651-62.3. Craig et al. Lancet Neurol. 2005 Mar.4(3):190-4.4. Duffy et al. Pharmacology, Biochemistry and Behaviour 75(2003) 721-729FOR FURTHER INFORMATION:Trond Syvertsen, CEO +47 23 01 09 60 / + 47 91 72 14 57Lars Helmer Enger, CFO +47 23 01 09 60 / + 47 90 84 37 71For information about Nutri Pharma and Nutri5®, see;http://www.nutripharma.com andwww.nutri5.comOslo, 22 October 2009This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 22.10.2009 - 18:53 Uhr
Sprache: Deutsch
News-ID 7300
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nutri5® and Brain Health related to treatment of menopausal symptoms"
steht unter der journalistisch-redaktionellen Verantwortung von
Nutri Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
